BTIG Maintains Buy on AtriCure, Raises Price Target to $63
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.
BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.